mRNA vaccine platforms and novel delivery systems: From mechanistic principles to clinical translation Authors: Yunchang Yang, Yunqin Sun, Xinyao Kang, Yaofeng Wang Published: 2025 ABSTRACT ABSTRACTMessenger RNA (mRNA) vaccines have revolutionized the field of vaccinology, offering rapid design flexibility, scalable manufacturing, and strong immunogenicity. The unprecedented success of COVID-19 mRNA vaccines has accelerated research into novel delivery platforms and expanded therapeutic applications beyond infectious diseases to cancer immunotherapy and immune-mediated disorders. This review provides a comprehensive overview of the mechanistic principles underlying mRNA vaccine design, including mRNA engineering strategies, delivery innovations such as lipid nanoparticles (LNPs), polymeric nanoparticles (PNPs), and virus-like particles (VLPs), as well as emerging needle-free administration technologies. We further highlight recent advances in therapeutic areas spanning infectious diseases (e.g. HIV, tuberculosis, respiratory syncytial virus), oncology, and non-traditional indications such as autoimmune disorders. Despite remarkable progress, critical challenges persist in vaccine stability, delivery efficiency, large-scale manufacturing, and global accessibility. Finally, we discuss future research directions integrating artificial intelligence, nanotechnology, and systems immunology to accelerate next-generation mRNA vaccine development and clinical translation.KEYWORDS: mRNA vaccines, lipid nanoparticles (LNPs), polymeric nanoparticles (PNPs), virus-like particles (VLPs), cancer immunotherapy, infectious diseases, needle-free delivery, vaccine stability, artificial intelligence, global health Introduction Since the outbreak of COVID-19, mRNA vaccines have rapidly emerged as a transformative technology in global vaccine development. The success of the Pfizer-BioNTech and Moderna vaccines not only underscored their critical role in controlling infectious diseases but also marked a breakthrough in vaccine technology. The unprecedented speed and flexibility of mRNA vaccine development confer distinct advantages in responding to emerging infectious diseases.1,2 By encoding pathogen-specific antigens, mRNA vaccines can rapidly elicit potent immune responses, a feature that drove their widespread adoption and recognition during the COVID-19 pandemic.3,4 The emergency use authorization and rapid global deployment of the Pfizer-BioNTech and Moderna vaccines demonstrated the feasibility of large-scale production and distribution, highlighting the transformative potential of mRNA technology in vaccinology.5 Moreover, the success of these vaccines has catalyzed the development of mRNA-based vaccines for other infectious diseases, including influenza, respiratory syncytial virus (RSV), and Ebola.6,7 The modular nature of mRNA vaccine design enables rapid adaptation to emerging viral variants and diverse pathogen targets. This versatility is exemplified by the successful development of mRNA vaccines against respiratory syncytial virus (RSV), a major cause of severe respiratory illness in infants and older adults for which no licensed vaccine existed until recently.8,9 The encoding of the prefusion-stabilized RSV F glycoprotein culminated in the 2024 FDA approval of Moderna’s mRNA-1345 for older adults.10–12 Similarly, mRNA platforms are being leveraged to target conserved epitopes in highly variable pathogens like HIV, which exhibits high mutation rates,13,14 aiming to elicit broadly neutralizing antibodies through structure-guided immunogen design.15,16 In tuberculosis (TB), mRNA vaccines encoding immunodominant antigens such as Ag85B are under preclinical investigation to elicit crucial Th1-type T-cell immunity.17 The platform has also demonstrated promising results against other emerging infectious threats, such as highly pathogenic avian influenza (H5N1), where mRNA vaccines conferred strong protection in animal models,18 validating its role as a versatile and rapid-response platform for future pandemic preparedness.19,20 The platform’s flexibility further extends to cancer immunotherapy, where mRNA vaccines have advanced along two primary trajectories: shared antigen vaccines targeting commonly expressed tumor-associated antigens (TAAs) such as KRASG12D, MAGE-A3, and NY-ESO-1,21–30 and personalized neoantigen vaccines that leverage genomic sequencing to target patient-specific mutations, demonstrating potent synergy with immune checkpoint inhibitors.31,32 Recent clinical breakthroughs with personalized neoantigen vaccines, such as BioNTech’s BNT122 and Moderna’s mRNA-4157, underscore the transformative progress in this field.33–35 Beyond infectious diseases, mRNA vaccine applications are expanding into broader therapeutic areas such as cancer immunotherapy and chronic infectious diseases (e.g., HIV, tuberculosis). In oncology, mRNA vaccines show considerable promise by encoding tumor-specific antigens – including neoantigens and tumor-associated antigens – to induce robust antitumor immune responses.36 Notably, mRNA vaccines can be employed as monotherapy or in combination with immune checkpoint inhibitors, chemotherapy, or adoptive cell therapies to overcome the immunosuppressive tumor microenvironment.37 Personalized mRNA vaccines targeting patient-specific neoantigens have further demonstrated substantial potential for individualized cancer immunotherapy.38,39 Despite these advances, the clinical translation of mRNA vaccines continues to face critical challenges. Key obstacles include limited delivery efficiency, suboptimal stability, scalability barriers in manufacturing, and issues surrounding global accessibility and cost.40 For instance, the inherent instability and susceptibility of mRNA to degradation necessitate the use of lipid nanoparticles (LNPs) as delivery vehicles; however, concerns remain regarding LNP-associated toxicity and stringent cold-chain requirements. Storage and transport limitations particularly constrain vaccine distribution in resource-limited settings, while large-scale production demands sophisticated process control and stringent quality assurance, posing logistical and economic burdens.41–44 Through sustained technological innovation and international collaboration, these challenges are expected to be progressively addressed, thereby unlocking the full potential of mRNA vaccines in global health.45 This review aims to comprehensively examine the mechanistic principles, delivery innovations, therapeutic applications, and translational challenges of mRNA vaccines, integrating insights from recent preclinical and clinical studies to delineate future directions in mRNA vaccine development. The molecular ballet: mechanistic principles of mRNA vaccines mRNA design and engineering The rational design of mRNA vaccines is a cornerstone of their success. Effective mRNA vaccines require both high immunogenicity and robust biological stability, typically achieved through chemical modifications and sequence engineering. Among the most widely used nucleotide modifications are pseudouridine (Ψ) and N1-methylpseudouridine (m1Ψ). These modifications enhance mRNA stability and translational efficiency while reducing innate immune recognition, thereby improving vaccine efficacy.46,47 Specifically, Ψ substitution stabilizes mRNA transcripts and increases protein yield, enhancing antigen expression and immunogenicity.46 Likewise, m1Ψ not only minimizes the activation of pattern-recognition receptors but also ensures accurate translation, thus improving safety and functional potency.48,49 In the context of COVID-19 vaccines, m1Ψ incorporation was pivotal to their clinical success, as modified mRNA demonstrated superior immunogenicity and tolerability compared with unmodified counterparts.48,49 The efficacy of mRNA vaccines depends on a multi-layered optimization strategy encompassing RNA structural elements, antigen engineering, and delivery systems. Foundational improvements include the 5′ cap structure and management of secondary structures to enhance translation and minimize aberrant innate immune activation.50,51 Beyond nucleotide modifications, untranslated regions (UTRs) are systematically optimized: the 5′ UTR is designed to be unstructured for efficient ribosome scanning, often using viral or computationally derived sequences, whereas the 3′ UTR – such as the human β-globin variant – enhances mRNA stability. Codon optimization prevents ribosomal stalling and increases protein yield. Recently, artificial intelligence has enabled the de novo design of superior UTRs; for example, the Smart5UTR tool generates m1Ψ-modified mRNA 5′ UTRs that improve translation and elicit stronger neutralizing antibody responses against SARS-CoV-2 variants than natural UTRs.52,53 Beyond conventional mRNA, self-amplifying RNA (saRNA) and circular RNA (circRNA) platforms offer distinct advantages. saRNA, derived from alphaviruses, enables intracellular amplification of antigen expression, allowing dose-sparing and heightened immunogenicity, as shown in mammalian and human skin models.54,55 Macrodomain mutations in saRNA nonstructural proteins reduce replication and innate immune activation while maintaining high protein expression,55 and delivery systems such as charge-neutralized polyplexes with γ-polyglutamic acid improve transfection and reduce cytotoxicity.56 In parallel, circRNA exhibits a covalently closed structure that confers high stability and sustained protein production due to exonuclease resistance, showing great potential for long-term therapeutic applications. Together, these advances expand the scope of mRNA therapeutics across infectious diseases, cancer, and genetic disorders. Structure-guided antigen design has been pivotal in maximizing the immunogenicity of mRNA vaccines across diverse pathogens. A seminal example is the prefusion-stabilized SARS-CoV-2 spike protein. The introduction of six proline substitutions in the HexaPro variant markedly enhanced protein expression and immunogenicity.57 Further refinements, including structure-guided mutations to lock the spike in its prefusion conformation58 and targeting conserved receptor-binding domain epitopes, have been crucial for broadening neutralization breadth against variants.59 This rational design paradigm has been successfully extrapolated to other targets, most notably respiratory syncytial virus (RSV), where stabilizing the prefusion F glycoprotein was instrumental in eliciting potent neutralizing antibodies, culminating in the 2024 regulatory approval of Moderna’s mRNA-1345 for older adults.10,11 Preclinical studies have corroborated the capacity of such mRNA vaccines to induce robust and durable immunity against RSV in both neonatal and adult animal models.60–62 However, the subsequent clinical hold on the pediatric development of mRNA-1345, prompted by observations of enhanced respiratory disease, underscores the population-specific nuances of safety and the complex interplay between antigen design and host immunity.10 This challenge is further exemplified by the Phase 3 outcome of the cytomegalovirus (CMV) vaccine mRNA-1647. Despite promising Phase 1/2 results that demonstrated robust neutralizing antibodies and cellular immunity,63 the trial did not meet its efficacy endpoints, highlighting that eliciting durable humoral and T-cell responses may be insufficient to prevent CMV infection or congenital transmission and pointing to critical gaps in understanding the correlates of protection for complex pathogens.64 Beyond single antigens, computationally designed nanoparticle platforms that display arrays of stabilized spikes have emerged as a powerful strategy to focus immune responses toward protective epitopes, yielding exceptionally potent and broad protection.65,66 The lipid nanoparticle (LNP) cargo Lipid nanoparticles represent the leading delivery platform for mRNA vaccines, providing essential protection against extracellular degradation and facilitating efficient cytosolic release. A typical LNP formulation consists of four key components – ionizable lipids, phospholipids, cholesterol, and PEG-lipids – each playing distinct yet complementary roles in determining the system’s physicochemical stability, biodistribution profile, and immunogenic potential.67–69 The ionizable lipid serves as the functional cornerstone of LNPs, with its chemical structure dictating delivery efficiency and cellular tropism. The evolution from first-generation ionizable lipids like DLin-MC3-DMA (used in Onpattro) to those employed in licensed mRNA vaccines (e.g., ALC-0315) involved systematic optimization of hydrocarbon tail length and unsaturation to enhance endosomal escape while reducing toxicity. Recent innovations include the incorporation of branched linkers, which significantly improve mRNA encapsulation and transfection efficiency without inducing systemic toxicity in preclinical models.67,70–72 Further advancing this paradigm, modular biodegradable ionizable lipids – such as linker-degradable ionizable lipids (LDILs) featuring disulfide-bridged ester linkers – have demonstrated superior endosomal disruption and rapid mRNA release, enabling highly efficient gene editing and enhanced splenic delivery.73 Helper lipids, including phospholipids and cholesterol, play critical roles beyond mere structural support. Phospholipids such as DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) enhance bilayer stability and promote membrane fusion with endosomal compartments, while also influencing organ tropism – for instance, DSPC-rich LNPs exhibit preferential accumulation in the spleen, unlike DOPE-based systems that target the liver.74,75 Cholesterol, constituting approximately 40% of the lipid composition, modulates membrane fluidity and structural integrity, and its derivatives have been shown to further refine biodistribution and immune activation.76 These components also contribute to immunomodulation, as evidenced by DSPC’s ability to promote dendritic cell maturation and tune T-helper responses.77 Polyethylene glycol (PEG)-lipids, though typically incorporated at low molar ratios, play an indispensable role in preventing particle aggregation and prolonging systemic circulation. However, PEGylation can also trigger anti-PEG immune responses – particularly IgM-mediated accelerated blood clearance (ABC) upon repeated administration – which remains a significant translational challenge.78–82 Innovative strategies to circumvent PEG-related immunogenicity include the use of alternative hydrophilic polymers such as gangliosides, which have been shown to attenuate anti-PEG IgM responses while maintaining favorable pharmacokinetic profiles.83–85 Finally, LNP physicochemical properties – including particle size, surface charge, and PEG chain length – exert profound effects on cellular uptake, lymphatic drainage, and endosomal escape. Smaller particles with optimized surface charge demonstrate enhanced tissue penetration and more potent adaptive immune activation, underscoring the importance of holistic LNP design in achieving efficacious mRNA delivery.86,87 Spatiotemporal dynamics of immunity The intricate interplay between mRNA formulations and the immune system represents a critical determinant of vaccine efficacy and safety. mRNA-LNP vaccines engage in a sophisticated molecular dialogue with the host immune system, where the balance between antigen expression and innate immune activation must be carefully calibrated. The self-adjuvanting properties of mRNA vaccines, mediated through pattern recognition receptors such as TLRs and RIG-I, provide essential costimulatory signals for robust adaptive immunity.88 However, excessive innate immune activation can both inhibit antigen translation and increase reactogenicity, necessitating precise engineering of mRNA molecules and delivery systems to optimize this balance. Recent advances in nucleoside modifications, codon optimization, and purification methods have significantly reduced dsRNA contaminants, thereby minimizing unintended inflammation while maintaining high antigen expression.46–49,89 This refined control over immune recognition expands the potential applications of mRNA technology beyond vaccines to include protein replacement therapies, where sustained protein expression with minimal inflammation is paramount. The immunological cascade initiated by mRNA vaccines involves spatiotemporally regulated interactions among multiple innate and adaptive immune compartments. Following intramuscular injection, mRNA-LNP complexes are primarily internalized by local dendritic cells (DCs) and macrophages, which subsequently migrate to draining lymph nodes. There, antigen expression and presentation by professional antigen-presenting cells (APCs) drive robust adaptive immune responses.90 This process is efficiently initiated by various administration routes. For example, upon intradermal administration, APCs in the skin efficiently capture and translate mRNA, presenting encoded antigens to naïve T cells within lymphoid tissues.88 Notably, minimal systemic proinflammatory cytokine release has been observed in preclinical models, underscoring the favorable safety profile of mRNA platforms88 (Figure 1). Mechanism of mRNA vaccine-induced immunity. Following intramuscular administration, mRNA-LNP complexes are internalized by local antigen-presenting cells (APCs), such as dendritic cells. The acidic environment of the endosome triggers protonation of ionizable lipids, leading to endosomal disruption and release of mRNA into the cytoplasm. The mRNA is translated into antigenic protein, which is processed and presented via MHC I and MHC II pathways to activate CD8+ and CD4+ T cells, respectively. This triggers a potent adaptive immune response, including T cell-mediated cytotoxicity and B cell differentiation into antibody-secreting plasma cells. The route of administration is a critical determinant of a vaccine’s immunological fate, influencing both the quality and magnitude of the immune response. Intramuscular (IM) injection, the standard for COVID-19 mRNA vaccines, has been shown to elicit robust systemic immunity, characterized by high levels of neutralizing antibodies and T-cell responses. However, the IM route may not be optimal for inducing mucosal immunity, which is crucial for preventing infection and transmission of respiratory pathogens like SARS-CoV-2. Studies have demonstrated that alternative routes, such as intranasal (IN) and intradermal (ID), can enhance mucosal immunity and offer dose-sparing benefits, which are particularly valuable in the context of vaccine shortages and global immunization efforts.91–93 The IM route is widely used due to its ability to induce strong systemic immune responses, as evidenced by the high levels of IgG antibodies and T-cell activation observed in various studies. For instance, the administration of mRNA vaccines via the IM route has been associated with significant increases in neutralizing antibody titers against SARS-CoV-2 variants, providing a robust defense against severe disease.94 However, the IM route’s limitation in inducing mucosal immunity has prompted exploration of alternative delivery methods. Intranasal vaccination, for example, has been shown to elicit superior mucosal and systemic immunity compared to IM vaccination, highlighting the potential of IN administration to enhance protective efficacy against respiratory viruses.91,92 Intradermal administration has also emerged as a promising alternative, offering comparable immunogenicity to IM injection while using lower doses of vaccine. This dose-sparing strategy not only conserves vaccine supply but also reduces systemic adverse events, making it a viable option for expanding vaccine coverage, especially in low- and middle-income countries.95,96 Additionally, studies comparing ID and IM routes have found that ID vaccination can induce similar or even higher cellular immune responses, despite lower humoral responses, suggesting that ID administration may be particularly beneficial for populations with vaccine hesitancy due to its favorable safety profile.97 In oncology, mRNA vaccines elicit potent tumor-specific CD8+ T-cell responses by coupling antigen translation with type I interferon signaling. Intratumoral and lymphoid APC subsets – including DCs and macrophages – play central roles in this process, linking innate sensing to adaptive immunity.98,99 Furthermore, local induction of interferon-β (IFN-β) at the injection site amplifies cytotoxic T-cell priming, enhancing antitumor immunity.100 The delivery frontier: innovations beyond the syringe Micro-delivery: LNPs and beyond The rapid expansion of mRNA therapeutics has catalyzed exploration beyond conventional lipid nanoparticles (LNPs) toward alternative nanocarrier systems designed to improve delivery efficiency, safety, and tissue specificity. Among these, polymeric nanoparticles (PNPs) have emerged as promising platforms due to their tunable physicochemical properties, low immunogenicity, and structural versatility. By modifying parameters such as polymer composition, molecular weight, and surface charge, researchers can optimize mRNA stability, release kinetics, and immune activation profiles. In cancer immunotherapy, PNPs have demonstrated considerable potential. For example, PTEN mRNA delivery using polymeric nanocarriers effectively restored PTEN expression in PTEN-deficient melanoma and prostate cancer cells, reversing the immunosuppressive tumor microenvironment and enhancing antitumor immune responses.101 Similarly, poly(β-amino ester)-based PNPs engineered for mRNA encapsulation exhibited efficient dendritic cell transfection and maturation in vitro, underscoring their utility in cancer vaccine development.102 Polymeric platforms have also been leveraged for pulmonary delivery. Inhalable PNP formulations enable localized transfection of lung epithelial and antigen-presenting cells, facilitating the development of mucosal mRNA vaccines against respiratory pathogens such as SARS-CoV-2. In murine models, inhaled PNP-based vaccines elicited robust humoral and cellular immunity, providing strong protection against respiratory viral challenges.103 Furthermore, poly (aspartic acid)-based PNPs have demonstrated efficient mRNA expression in both lung and muscle tissues following intravenous and intramuscular administration, respectively, highlighting their versatility for systemic and localized delivery.104 Regarding safety, PNP formulations have shown reduced inflammatory profiles compared with conventional LNPs. Notably, poly(hydrophobic amino acid)-based carriers successfully delivered mRNA cancer vaccines while inducing potent CD8+ T-cell responses with negligible inflammatory side effects.105 Additionally, oral and gastrointestinal delivery of mRNA vaccines using poly(β-amino ester) nanoparticles induced both humoral and cellular immunity in preclinical models, with formulations stable for prolonged periods at 4°C, suggesting significant potential for simplified storage and distribution.106 Another promising strategy involves virus-like particles (VLPs), which mimic viral morphology while lacking infectious genetic material, thereby combining high immunogenicity with intrinsic biosafety.107,108 Advances in chemical and genetic engineering have enabled surface functionalization of VLPs, enhancing their pharmacokinetics, tissue targeting, and stability.109 VLP-based systems have been successfully applied for the delivery of nucleic acids, proteins, small-molecule therapeutics, and gene-editing tools such as CRISPR-Cas9, opening new avenues for mRNA therapeutics and gene therapy.110–112 Virus-like particles (VLPs) offer a promising biomimetic delivery strategy by packaging mRNA within a protein shell that mimics a native virus but lacks the ability to replicate. This unique characteristic enables VLPs to serve as safe and effective platforms for vaccine development and therapeutic delivery. The structural mimicry of VLPs allows them to engage the immune system similarly to natural viruses, thereby inducing potent immune responses without the risk of infection. This is particularly advantageous in the context of mRNA vaccines, where the delivery of genetic material needs to be both efficient and safe.113,114 The versatility of VLPs in vaccine development is exemplified by their application in combating various infectious diseases, including SARS-CoV-2. For instance, the engineering of SARS-CoV-2 VLPs has demonstrated enhanced mRNA delivery capabilities, allowing for the efficient transduction of human cells and the potential for gene editing applications.112 This is achieved through molecular engineering techniques that optimize the VLP platform for mRNA delivery, thereby overcoming natural biological barriers and enabling targeted delivery to specific tissues.115 The ability to program viral tropism by switching glycoproteins further enhances the specificity and efficacy of VLP-based delivery systems.112 Moreover, VLPs have shown significant potential in the field of cancer immunotherapy. By leveraging their structural attributes and modification capabilities, VLPs can effectively deliver tumor antigens, stimulating the immune system to target and eradicate tumor cells.114 This is complemented by the ability of VLPs to encapsulate and protect RNA molecules, ensuring the stability and integrity of the therapeutic cargo during delivery.115 The encapsulation of functional proteins within VLPs further expands their application in biomedicine, offering enhanced stability and targeted delivery for therapeutic interventions.110 Macro-delivery: needle-free administration Needle-free delivery technologies offer significant advantages for large-scale vaccination campaigns by addressing challenges associated with conventional needle-based injections, including needle-stick injuries, injection pain, and vaccine hesitancy.116 In outbreak settings, these technologies enable rapid, mass immunization while reducing healthcare infrastructure requirements.117 Microneedle patches have emerged as a versatile and promising platform for transdermal drug and vaccine delivery, offering a minimally invasive and patient-friendly alternative to conventional hypodermic injections. These patches function by creating transient microchannels in the skin to deliver their payload directly into the immune-cell-rich epidermis and dermis, thereby facilitating efficient transdermal transport.118,119 They are generally categorized into several types – including dissolvable, coated, and hollow microneedles – each with distinct mechanisms and applications. Dissolvable microneedles, fabricated from biodegradable polymers, completely dissolve within the skin to release encapsulated drugs or vaccines, leaving no sharp waste and making them particularly suitable for delivering biologics and vaccines.120 Their development has been advanced through innovative materials, such as cyclodextrin derivatives, which confer robust mechanical strength and ultrafast dissolution for rapid therapeutic action.121 Coated microneedles, on the other hand, are solid structures coated with a drug formulation that is deposited upon skin insertion, ideal for the rapid delivery of drugs requiring quick onset, as demonstrated in studies for metformin delivery in type 2 diabetes.122 Hollow microneedles, which administer liquid formulations directly into the skin, are advantageous for delivering larger volumes; their efficacy, for instance in transdermal insulin delivery, has been enhanced by oscillation techniques that improve insertion depth and consistency.123 The application of microneedle technology spans diverse therapeutic areas. In vaccinology, dissolvable microneedle patches enable dose-sparing immunization and enhance thermostability, mitigating cold-chain dependence and improving accessibility in low-resource settings.117,124 Preclinical studies, such as those with influenza vaccines, have shown that dissolvable microneedles can elicit strong immune responses without significant skin irritation, even when co-formulated with adjuvants like monophosphoryl lipid A (MPL).125–127 Beyond vaccines, this platform has been successfully leveraged for conditions like rheumatoid arthritis, where an active dissolvable microneedle patch with spontaneous bubble generation demonstrated superior efficacy,128 and for ocular delivery via hollow microneedles enabling minimally invasive suprachoroidal injections.129 The integration of nanotechnology further augments their potential, as seen in liposome-loaded dissolvable microneedles for enhanced intradermal delivery of the Hepatitis B vaccine.4 Ongoing research is focused on overcoming challenges in scalability and manufacturing through advanced fabrication techniques like 3D printing and micromolding, which allow for precise geometric control.130 The use of biodegradable and biocompatible materials remains a priority to ensure safety and efficacy.131 As the field evolves, microneedle patches are poised to play a pivotal role in the future of transdermal drug delivery, combining minimal invasiveness with precision and broad applicability.132 Jet injection systems, which propel vaccines into the skin using high-pressure streams, also enable precise, rapid, and needle-free delivery.133,134 Electronic control over injection parameters allows optimization of depth and dose, improving delivery consistency while minimizing pain and tissue trauma. Emerging approaches such as microneedle patches and inhalable formulations further expand the scope of needle-free delivery. Microneedle patches create transient microchannels in the skin to facilitate transdermal vaccine transport, reducing biohazardous waste associated with conventional syringes.119 For instance, dissolvable microneedle patches delivering influenza vaccines in murine models elicited strong immune responses with no significant skin irritation, even when incorporating adjuvants such as monophosphoryl lipid A (MPL).125–127 In respiratory infections, inhalable mRNA vaccines offer direct mucosal immunization at the site of pathogen entry, inducing both systemic and mucosal immunity. Recent studies have demonstrated the efficacy of inhaled mRNA vaccines against RSV and influenza, highlighting their potential for pandemic preparedness.127 Figure 2 and Table 1 shows the traditional injection and the emerging needle-free injection. The choice of delivery route and technology is paramount, as it determines the initial cellular tropism (e.g., targeting epidermal Langherhans cells with microneedles versus lung alveolar macrophages with inhalation), which in turn can profoundly shape the quality, magnitude, and durability of the adaptive immune response.135 Innovations in mRNA vaccine delivery systems. A comparison of traditional and novel delivery platforms. (A) Intramuscular injection using a conventional syringe. (B) Microneedle patches painlessly deliver vaccine to the immune-cell-rich dermis. (C) Jet injectors use a high-pressure stream for needle-free delivery. (D) Inhalable formulations target the respiratory mucosa, inducing localized immunity. These alternative systems aim to improve patient compliance, enable self-administration, reduce cold-chain dependence, and elicit mucosal immunity. Table 1.Key characteristics and trade-offs of major mRNA delivery platforms.PlatformCompositionAdvantagesLimitationsPrimary ApplicationsReferencesLNPIonizable lipid, phospholipid, cholesterol, PEG-lipidHigh delivery efficiency, proven clinical success, scalable manufacturingPotential reactogenicity, cold chain requirement, PEG-associated hypersensitivity (rare)Prophylactic vaccines (e.g., COVID-19), therapeutic vaccines, protein replacement67–69,71–73Polymer NPCationic or biodegradable polymers (e.g., PBAE, PLGA)Tunable properties, potential for improved biocompatibility, diverse polymer librariesOften lower transfection efficiency than LNPs, complexity in synthesis and characterizationCancer immunotherapy, mucosal vaccination, localized delivery101–106VLPViral structural proteinsHigh immunogenicity (self-adjuvanting), precise structure, inherent tropismComplex production, limited packaging capacity, potential pre-existing immunityVaccines (eucaryotic expression), targeted delivery107–110,110,112Note: LNP, lipid nanoparticle; NP, nanoparticle; PEG, polyethylene glycol; PBAE, poly(beta-amino ester); PLGA, poly(lactic-co-glycolic acid); VLP, virus-like particle. Key characteristics and trade-offs of major mRNA delivery platforms. Note: LNP, lipid nanoparticle; NP, nanoparticle; PEG, polyethylene glycol; PBAE, poly(beta-amino ester); PLGA, poly(lactic-co-glycolic acid); VLP, virus-like particle. Navigating the translational valley: critical challenges Safety and reactogenicity Safety remains a primary concern in the clinical deployment of mRNA vaccines. Although clinical trials and real-world data have confirmed favorable safety profiles, rare but notable adverse events – such as myocarditis and anaphylaxis – have been documented.136,137 While the incidence of these events is low, their potential severity necessitates ongoing pharmacovigilance and mechanistic investigations. During the COVID-19 pandemic, the accelerated development timelines and emergency use authorizations raised public concerns regarding long-term safety.138,139 Evidence to date indicates that most adverse events are transient, mild-to-moderate local or systemic reactions, such as injection-site pain or short-term fever.140 Nevertheless, long-term safety data remain limited, particularly in special populations including immunocompromised individuals and patients with autoimmune diseases.141 As mRNA vaccine platforms expand to new indications, comprehensive safety monitoring will be essential to build public confidence and regulatory acceptance. The complex interplay between mRNA formulations and the immune system also manifests in population-specific responses, as evidenced by the divergent outcomes of RSV vaccination across age groups. While mRNA-1345 demonstrated high efficacy and was well-tolerated in older adults,11,142 the observation of enhanced respiratory disease in pediatric populations led to a clinical hold.10 Similarly, the failure of CMV vaccine candidate mRNA-1647 despite robust immunogenicity in early-phase trials underscores that our understanding of correlates of protection remains incomplete for certain pathogens.63,64 These cases highlight that the balance between immunogenicity and safety must be evaluated within specific biological contexts. Intriguingly, a recent large retrospective analysis revealed that administration of SARS-CoV-2 mRNA vaccines was associated with significantly improved overall survival in cancer patients receiving immune checkpoint inhibitors (ICIs), suggesting that the immunostimulatory nature of mRNA-LNP formulations may provide a nonspecific synergistic benefit to enhance the efficacy of cancer immunotherapy.143 Manufacturing and supply chain The transition of mRNA vaccine production from laboratory-scale development to global deployment presents formidable logistical and technological obstacles, with cold-chain requirements representing a particularly critical barrier. The inherent instability of both mRNA molecules and lipid nanoparticle (LNP) formulations necessitates storage at ultralow temperatures (−20°C to −80°C) to maintain therapeutic efficacy during distribution and storage. This strict thermal dependence severely restricts vaccine accessibility in resource-limited regions that lack reliable refrigeration infrastructure, creating significant equity gaps in global health responses to emerging infectious threats.144,145 The underlying instability stems from multiple physicochemical vulnerabilities. mRNA is chemically prone to hydrolysis and fragmentation under suboptimal conditions, while LNPs face challenges including lipid phase separation, particle aggregation, and ice-induced structural damage during freeze-thaw cycles. These degradation pathways are influenced by various external factors including temperature fluctuations, pH variations, and interfacial stress during processing and storage. Understanding these mechanisms is essential for developing effective stabilization strategies that can extend shelf-life and reduce cold-chain dependency.146,147 To address these stability challenges, multiple innovative approaches are being pursued. Lyophilization (freeze-drying) has emerged as a particularly promising technology for enhancing thermostability, with several mRNA-LNP formulations demonstrating maintained immunogenicity after storage at refrigerated or even ambient temperatures following lyophilization. Complementary strategies include the incorporation of cryoprotectants such as sucrose to stabilize the lipid matrix during freezing, optimization of mRNA solution pH to improve encapsulation efficiency and biological activity, and the engineering of novel ionizable lipids with improved thermal stability. Additionally, the use of stabilizing agents like recombinant apolipoprotein E3 (ApoE3) has shown promise in maintaining LNP integrity through reversible interfacial binding during temperature stress.147–152 Moreover, the complex processes involved in producing and releasing mRNA-based products demand rigorous quality control (QC) measures to ensure product safety and efficacy. Critical quality attributes (CQAs) must be strictly monitored throughout manufacturing, particularly focusing on RNA purity with emphasis on limiting double-stranded RNA (dsRNA) contaminants – known to potently activate innate immune pathways and potentially inhibit translation. Equally important is quantifying the percentage of fully capped mRNA species, as uncapped or improperly capped transcripts exhibit reduced translational efficiency and increased immunogenicity. Additionally, comprehensive characterization of ionizable lipid-mRNA adduct formation is essential, as these covalent modifications can adversely impact mRNA release kinetics and overall delivery efficiency. Advanced analytical techniques including capillary electrophoresis, liquid chromatography-mass spectrometry, and novel immunoassays are being implemented to monitor these CQAs, ensuring consistent production of high-quality mRNA therapeutics.89,153,154 Beyond stability concerns, manufacturing scale-up faces additional hurdles in process standardization, raw material supply chain reliability, and regulatory compliance. Traditional small-scale batch processes are poorly suited to meet global demand, prompting the development of continuous manufacturing platforms such as microfluidic-based systems that enable high-throughput LNP production while preserving critical quality attributes. These technological advances, coupled with improved process analytical technologies (PAT) for quality control, are helping to streamline manufacturing pipelines, reduce production costs, and enhance preparedness for future pandemic-scale vaccine requirements155,156 (Table 2). Table 2.Critical barriers in the clinical translation of mRNA vaccines and emerging strategies to address them.Challenge CategorySpecific ChallengePotential Solutions/Emerging TechnologiesStage of DevelopmentReferencesSafety & ReactogenicityInnate immune activation, rare adverse events (e.g., myocarditis)Novel nucleoside modifications, optimized UTRs, biodegradable ionizable lipids, alternative PEG-less formulations (e.g., gangliosides)Preclinical research & early clinical trials for new platforms46–49,52,83,84,136–141Stability & StorageCold chain dependency (−20°C to −80°C)Lyophilization (freeze-drying), advanced LNP formulations with improved thermostability, solid-dose formulations (e.g., microneedle patches)Lyophilized COVID-19 vaccines in clinical use; ongoing research for broader application41,144–152Manufacturing & ScalabilityComplex process control, supply chain for specialty lipidsContinuous manufacturing (e.g., microfluidics), process analytical technology (PAT), design of readily available lipid componentsScaling up for global production; ongoing process optimization43,44,155,156Equity & AccessHigh cost, intellectual property, centralized productionTechnology transfer hubs (e.g., WHO mRNA hub), regional manufacturing facilities, development of low-cost, shelf-stable forEarly-stage initiatives; significant political and economic hurdles remain40,44,45,144Note: UTR, untranslated region; PEG, polyethylene glycol; LNP, lipid nanoparticle; PAT, process analytical technology. Critical barriers in the clinical translation of mRNA vaccines and emerging strategies to address them. Note: UTR, untranslated region; PEG, polyethylene glycol; LNP, lipid nanoparticle; PAT, process analytical technology. Future perspectives and concluding remarks Future research directions Over the next five years, research on mRNA vaccines is expected to focus on several key priorities: Stability and storage optimization: Developing formulations with long-term stability at ambient or standard refrigeration temperatures to minimize cold-chain dependency. Next-generation vaccine targets: Designing mRNA vaccines for drug-resistant pathogens, including multidrug-resistant Mycobacterium tuberculosis and other antimicrobial-resistant bacteria. Artificial intelligence and computational modeling: Integrating AI-driven antigen prediction and computational optimization of delivery systems, such as lipid composition and nanoparticle design, to accelerate rational vaccine development and enhance translational efficiency. These innovations aim to overcome existing limitations in distribution logistics, manufacturing scalability, and immune specificity, ultimately broadening the clinical applications of mRNA vaccines. Looking beyond infectious diseases and oncology, mRNA-based platforms are emerging as powerful tools for immune modulation. By encoding disease-specific autoantigens or tolerogenic epitopes, mRNA vaccines can be designed to promote antigen-specific immune tolerance – offering a novel therapeutic strategy to recalibrate dysregulated immune responses in autoimmune disorders such as multiple sclerosis (MS) and rheumatoid arthritis.157–161 In allergic diseases, preclinical studies of tolerogenic mRNA-LNP vaccines have demonstrated significant potential to redirect pathogenic immune responses toward tolerance by expanding antigen-specific regulatory T cells (Tregs) and inducing blocking IgG antibodies.162–164 The integration of mRNA-LNP technology with modern immunotherapy frameworks represents a promising pathway for next-generation treatments of complex immune-mediated diseases.164,165 Conclusion mRNA vaccine technology represents a paradigm shift in vaccinology and immunotherapy, offering unprecedented flexibility, scalability, and precision in combating infectious diseases, cancers, and immune-mediated disorders. The rapid success of COVID-19 mRNA vaccines has demonstrated the transformative potential of this platform, while ongoing advances in delivery systems, stability engineering, and computational design are poised to unlock broader clinical applications. With sustained multidisciplinary collaboration spanning molecular biology, nanotechnology, computational science, and public health, mRNA vaccines are well positioned to address both current global health challenges and emerging infectious threats, driving the next era of innovation in immunology and vaccinology. Acknowledgments Thanks to all authors for their contributions. Graphical Abstract, Figures 1 and 2 Created in BioRender. (2025) https://BioRender.com/jujb9bf (Created in BioRender. 李, 泽. (2025) https://BioRender.com/fie2dro). YY, YW contributed to conceptualization, supervision and writing—review and editing. XK and YS contributed to printing. All authors contributed to the article and approved the submitted version. Biographies Yunchang Yang, holds the position of North henan medical university. His primary research interests lie in the fields of vaccinology, infectious diseases (particularly tuberculosis), and the application of epidemiological methods in clinical research. His work has been published in journals such as Frontiers in Cellular and Infection Microbiology. With experience as a peer reviewer for several SCI-indexed journals, Dr. Yang is actively engaged in the scientific community. Yunqin Sun, Professor, is affiliated with Northern Henan Medical College. She is mainly engaged in clinical teaching and scientific research, with her research interests focusing on targeted cancer therapy and immune regulation. She has published a number of articles indexed in SCI (Science Citation Index). Xinyao Kang, is a graduate student of Henan University. Her main research field involves the extraction of natural drug components,mRNA Vaccine Platforms and the study of their functional mechanisms. He actively devoted himself to the field of scientific research and studied relevant theoretical knowledge in depth. Yaofeng Wang, Professor, Master’s Supervisor, works at Henan Yubei Medical College. His primary research focuses on vaccines, infectious diseases, and other related fields. He has published over 20 papers in domestic and international academic journals, covering areas such as environmental toxicology and clinical oncology. He has authored or edited 3 monographs. Funding Statement This study was financially supported by a research fund from the Backbone teachers Programs of North henan medical university [SQ2023GGJS02]. Disclosure statement No potential conflict of interest was reported by the author(s). Consent for publication All authors read and approved the final version of the manuscript References